PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE

100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:


Scientific evidence for clinical utility.

By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.

Evidence

A Gene Expression Profile for Detection of Sufficient Tumour Cells in Breast Tumour Tissue: Microarray Diagnosis Eligibility

PUBLICATION: BMC Med Genomics. 2009 Aug 12;2:52. doi: 10.1186/1755-8794-2-52. AUTHORS: Roepman P., Schuurman A., Delahaye L.J., Witteveen A.T., Floore A.N., Glas A.M. SUMMARY: The developed 13-gene profile provides an objective tool for assessment whether a breast cancer sample contains sufficient tumour cells for microarray diagnostics. Read more: A Gene-Expression Profile... Read More

The 70-gene Prognosis-Signature Predicts Disease Outcome in Breast Cancer Patients with 1-3 Positive Lymph Nodes in an Independent Validation Study

PUBLICATION: Breast Cancer Res Treat. 2009 Jul;116(2):295-302. doi: 10.1007/s10549-008-0130-2. Epub 2008 Jul 27. AUTHORS: Mook S., Schmidt M.K., Viale G., Pruneri G., Eekhout I., Floore A., Glas A.M., Bogaerts J., Cardoso F., Piccart-Gebhart M.J., Rutgers E.T., Van't Veer L.J.; TRANSBIG Consortium. SUMMARY: Among 1-3 LN+ patients, the 10-year distant metastasis-free Read More

Daily Clinical Practice of Fresh Tumour Tissue Freezing and Gene Expression Profiling; Logistics Pilot Study Preceding the MINDACT Trial

PUBLICATION: Eur J Cancer. 2009 May;45(7):1201-1208. doi: 10.1016/j.ejca.2009.01.004. Epub 2009 Feb 14. AUTHORS: Mook S., Bonnefoi H., Pruneri G., Larsimont D., Jaskiewicz J., Sabadell M.D., MacGrogan G., Van't Veer L.J., Cardoso F., Rutgers E.J. SUMMARY: Tumour samples were obtained in 60 of 64 patients. Among the 60 samples, 11 contained Read More

Constructive Technology Assessment (CTA) as a Tool in Coverage with Evidence Development: The Case of the 70-gene Prognosis Signature for Breast Cancer Diagnostics

PUBLICATION: Int J Technol Assess Health Care. 2009 Jan;25(1):73-83. doi: 10.1017/S0266462309090102. AUTHORS: Retèl V.P., Bueno-de-Mesquita J.M., Hummel M.J., van de Vijver M.J., Douma K.F., Karsenberg K., van Dam F.S., van Krimpen C., Bellot F.E., Roumen R.M., Linn S.C., van Harten W.H. SUMMARY: Differences in speed of implementation and influenced treatment Read More

Clinical Application of the 70-gene Profile: The MINDACT Trial

PUBLICATION: J Clin Oncol. 2008 Feb 10;26(5):729-35. doi: 10.1200/JCO.2007.14.3222. AUTHORS: Cardoso F., Van't Veer L., Rutgers E., Loi S., Mook S., Piccart-Gebhart M.J. SUMMARY: Its prospective validation is currently ongoing through the MINDACT (Microarray in Node-Negative Disease May Avoid Chemotherapy) trial, a 6,000-patient randomized, multicentric trial. This article reviews the Read More

Use of 70-gene Signature to Predict Prognosis of Patients with Node-Negative Breast Cancer: A Prospective Community-Based Feasibility Study (RASTER)

PUBLICATION:  Lancet Oncol. 2007 Dec;8(12):1079-1087. doi: 10.1016/S1470-2045(07)70346-7. Epub 2007 Nov 26. AUTHORS:  Bueno-de-Mesquita J.M., van Harten W.H., Retel V.P., van't Veer L.J., van Dam F.S., Karsenberg K., Douma K.F., van Tinteren H., Peterse J.L., Wesseling J., Wu T.S., Atsma D., Rutgers E.J., Brink G., Floore A.N., Glas A.M., Roumen R.M., Read More